Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels. The findings, which were recently published in Cell Death Discovery, showed that using eliglustat, an FDA-approved drug, induced cell death in several cancer cell lines. Additionally, the findings demonstrated, for the first time, that GCS and its products had a pro-survival role in cancer cells.